Biotherapeutics need general chapters not individual Ph. Eur. monographs says EGA

By Gareth Macdonald contact

- Last updated on GMT

EGA wants general chapters for biotherapeutics
EGA wants general chapters for biotherapeutics
Generic drugmakers want biotherapeutic products to have general recommendations in the European Pharmacopoeia rather than individual monographs.

The suggestion was put forward by Karina Boszko, from Polish API maker Polpharma, who told delegates at the European Directorate for the Quality of Medicines’ (EDQM) 50th​ anniversary conference in Strasbourg that biotherapeutics are a special case.

Biotherapeutic products should not have the same monographs as medical products”​ she said, adding that instead the EDQM should focus on developing “general recommendations and requirements for their characterisation​.”  

Boszko, who was representing the European Generic Medicines Association (EGA), added by taking this approach the “European pharmacopoeia would establish defined general rules for the biotechnology industry and regulators worldwide​.”

State of play

There are dedicated Ph. Eur. groups covering biologicals, blood products, single source biopharmaceutical products, raw materials for cell based therapy products and monoclonal antibodies.

Two of these – those concerned with biologics and blood products – already develop individual monographs. The raw materials group, in contrast, elaborates a general chapter on raw materials for cell based and gene therapy products.

An EDQM spokeswoman told there are a “wide range of biotherapeutic products for which the Ph. Eur. needs to adapt its approach regarding general or individual monographs.  

"In addition, it is not possible to elaborate one general monograph to cover such a wide range of products.”

Despite this she acknowledged that: “Monographs for biotherapeutic products need more flexibility than a monograph for a chemically defined substance.

As we gain more experience the Ph. Eur. is translating the flexibility info working reality​,” she continued, adding that “this has already started with the monograph on Factor IX recombinant​.” 

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more